SightfileU.S. market data from official filings

KURA ONCOLOGY INC COM (KURA)

Name: KURA ONCOLOGY INC COM (KURA) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001422143 · EDGAR filings · Updated 2026-06-22

KURA ONCOLOGY INC COM (KURA) has reported institutional ownership of 95.5%, with 218 institutional managers holding positions valued at $686.1M per the latest 13F reporting period.

Institutional ownership

95.5%

Institutional managers

218

Reported 13F value

$686.1M

Insider activity

55 trans.

−$1.15M net selling

Latest updates

2026-06-22 — Insider transaction reported (Form 4)
2026-06-18 — Notice of proposed sale filed (Form 144)
2026-06-04 — Insider transaction reported (Form 4)
2026-06-04 — Insider transaction reported (Form 4)
2026-06-04 — Insider transaction reported (Form 4)
2026-06-04 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, KURA ONCOLOGY INC COM has 218 institutional holders and institutional ownership of 95.5%.

Insider activity

Insiders reported 55 transactions (3 buys, 31 sells) across 9 reporting insiders, with a net reported value of −$1.15M.

Related companies

VOR BIOPHARMA INC (VOR) · JADE BIOSCIENCES INC (JBIO) · LB PHARMACEUTICALS INC (LBRX) · CASTLE BIOSCIENCES INC (CSTL) · BRIGHT MINDS BIOSCIENCES INC (DRUG) · GH RESEARCH PLC (GHRS)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-22.